February 2020

No More ‘Sucker at the Table’: New Coalition to Represent Fortune 500 Firms Paying Prescription Drug Bills

2020-02-04T16:36:38-05:00February 4th, 2020|Drug Cost News, EmployersRx, News|

Tired of being "the sucker at the table," a group representing Fortune 500 companies has formed a lobby to push congressional drug-pricing policies that focus beyond Medicare. Employers' Prescription for Affordable Drugs has described its goal as "to mobilize large employers to drive down prescription drug costs by advocating for public policies based on increased competition,

Employers Shoulder Plenty of Drug Costs, but Haven’t Lobbied Much to Lower Them — Until Now

2020-02-03T12:08:36-05:00February 3rd, 2020|Drug Cost News, EmployersRx, News|

Legislation aiming to reduce drug prices has thus far focused on changes to federal programs such as Medicare. But Walmart, Pepsi, and other large companies provide employer-sponsored health insurance to more than 150 million Americans, making them the largest footers of health bills. Now, these employers and a coalition of other Fortune 500 companies also

January 2020

Coalition Advocates for Biosimilar Uptake to Help Lower Employers’ Drug Cost Burden

2020-01-21T14:05:14-05:00January 21st, 2020|Drug Cost News, EmployersRx, News|

Rising drug costs in the United States are a pressing concern not only for patients who need to receive those drugs, but also for employers. The Employers’ Prescription for Affordable Drugs (EmployersRx) is a coalition that aims to tackle this problem by working with policy makers and stakeholders to encourage and facilitate more transparency, competition,

EmployersRx on “Not So Different”: Employers Advocate for Lower Drug Costs Through Biosimilars

2020-01-15T12:00:25-05:00January 15th, 2020|Drug Cost News, EmployersRx, News|

With pharmaceutical spending at record levels, employers are looking for solutions and are hopeful that biosimilars can play a role in controlling costs. On this episode of "Not So Different," Elizabeth Mitchell and Lauren Vela (from EmployersRx founding member Pacific Business Group on Health) spoke with Allison Inserro of The Center for Biosimilars about the

November 2019

New Analysis Finds Large Drugmakers Could Lose $1 Trillion in Sales and Still Be the Most Profitable Industry

2019-11-15T12:34:05-05:00November 15th, 2019|Drug Cost News, News|

A new analysis of publicly reported financial data by researchers at West Health Policy Center and Johns Hopkins Bloomberg School of Public Health finds that large, brand-name drug manufacturers would still be the most profitable industry sector even with $1 trillion in lower sales, all while maintaining current research investments. Read about the report's findings >

October 2019

September 2019